Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
about
Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinomaCabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Clinical outcome of patients with pancreatic metastases from renal cell cancerA retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapyPostoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinomaSulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation.Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma.The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma.Features, risk factors and clinical outcome of "very late" recurrences after surgery for localized renal carcinoma: A retrospective evaluation of a cohort with a minimum of 10 years of follow up.Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience.Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents.[Focal therapy for small renal masses : Observation, ablation or surgery].Clinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery.
P2860
Q28072166-7AA8EF13-63D0-45AD-B274-61608D31AAF4Q33758217-0B26D308-6491-4E12-B652-5693A5E1C6A2Q34495684-A71B6C12-B3FA-4EA1-B9FE-0F57C06824DDQ35083485-FB4936F6-08C5-4336-AD85-E50DFE059C1DQ35095830-6F4C497E-7EF4-4349-A1E7-4FF0153669DBQ36092829-6DDC8D24-38F2-4FA7-8460-28E7DFF4DDCEQ36303564-E0DA588C-D6CD-40BF-ABDF-54941478E099Q37709114-E9F3AD94-F216-49F9-A8EF-1B4AECA809CEQ38202060-2C76368D-FC3D-4117-B5D7-A2CDD77C16E2Q38794217-F9F4FD44-EF25-4CA4-ADA4-D57FC5A962A8Q38868038-786DBC0C-01F7-49F5-9E00-2A9A505B255FQ39090533-1F98852B-B8ED-4051-B3FE-0148FC3E4B66Q39136550-D6B8BF47-31BD-45DC-91E8-E89D8BE7F0B4Q40322702-6D6F10F3-D729-4EA4-A589-1054AD4EC933Q41624982-CD82DCDB-B71B-49FC-819A-692854ADE3F8Q46106579-E44D4049-4379-4C4B-A0B9-4252379B866EQ47132952-E1CFFFFA-7B29-4C44-88A1-8A91B44A483BQ47149978-F135EDBB-DBA9-4BDD-86FC-4CECB02F7B46Q47158686-B4C247B1-DE52-4352-A8CC-0C836E9E8484Q50240365-06954CD6-8B9A-47D0-9DD4-933C4312E710Q51788363-D0B4BCA9-EC9E-4B59-B612-68DD68429467
P2860
Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Survival outcome and treatment ...... n the era of targeted therapy.
@ast
Survival outcome and treatment ...... n the era of targeted therapy.
@en
Survival outcome and treatment ...... n the era of targeted therapy.
@nl
type
label
Survival outcome and treatment ...... n the era of targeted therapy.
@ast
Survival outcome and treatment ...... n the era of targeted therapy.
@en
Survival outcome and treatment ...... n the era of targeted therapy.
@nl
prefLabel
Survival outcome and treatment ...... n the era of targeted therapy.
@ast
Survival outcome and treatment ...... n the era of targeted therapy.
@en
Survival outcome and treatment ...... n the era of targeted therapy.
@nl
P2093
P50
P1433
P1476
Survival outcome and treatment ...... in the era of targeted therapy
@en
P2093
Aristotelis Bamias
Brian I Rini
Christian K Kollmannsberger
Daniel Y C Heng
Jae-Lyn Lee
Jennifer J Knox
Mary J MacKenzie
Min-Han Tan
Neeraj Agarwal
P304
P356
10.1016/J.EURURO.2013.07.031
P407
P577
2013-07-30T00:00:00Z